Woodward Diversified Capital LLC bought a new stake in Cardinal Health, Inc. (NYSE:CAH - Free Report) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund bought 1,782 shares of the company's stock, valued at approximately $299,000.
Several other institutional investors also recently bought and sold shares of CAH. Wellington Management Group LLP grew its position in Cardinal Health by 1,666.7% in the 1st quarter. Wellington Management Group LLP now owns 2,384,192 shares of the company's stock valued at $328,470,000 after acquiring an additional 2,249,241 shares in the last quarter. JPMorgan Chase & Co. grew its position in Cardinal Health by 40.0% in the 1st quarter. JPMorgan Chase & Co. now owns 4,175,992 shares of the company's stock valued at $575,327,000 after acquiring an additional 1,193,983 shares in the last quarter. Zurich Insurance Group Ltd FI grew its position in Cardinal Health by 4,935.9% in the 1st quarter. Zurich Insurance Group Ltd FI now owns 946,750 shares of the company's stock valued at $130,434,000 after acquiring an additional 927,950 shares in the last quarter. Nuveen LLC acquired a new position in Cardinal Health in the 1st quarter valued at about $106,065,000. Finally, T. Rowe Price Investment Management Inc. acquired a new position in Cardinal Health in the 1st quarter valued at about $104,951,000. 87.17% of the stock is owned by institutional investors and hedge funds.
Cardinal Health Stock Up 0.4%
Shares of CAH opened at $158.50 on Friday. The stock has a 50 day moving average price of $152.12 and a 200 day moving average price of $150.09. The company has a market capitalization of $37.66 billion, a price-to-earnings ratio of 24.57, a price-to-earnings-growth ratio of 1.34 and a beta of 0.71. Cardinal Health, Inc. has a 52-week low of $106.98 and a 52-week high of $168.44.
Cardinal Health (NYSE:CAH - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported $2.08 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.03 by $0.05. The firm had revenue of $60.16 billion during the quarter, compared to the consensus estimate of $60.91 billion. Cardinal Health had a negative return on equity of 74.45% and a net margin of 0.70%.The firm's quarterly revenue was up .5% compared to the same quarter last year. During the same period in the prior year, the company posted $1.84 earnings per share. Cardinal Health has set its FY 2026 guidance at 9.300-9.500 EPS. On average, equities analysts anticipate that Cardinal Health, Inc. will post 7.95 EPS for the current fiscal year.
Cardinal Health Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Wednesday, October 1st will be paid a $0.5107 dividend. The ex-dividend date is Wednesday, October 1st. This represents a $2.04 dividend on an annualized basis and a yield of 1.3%. Cardinal Health's payout ratio is currently 31.63%.
Insider Buying and Selling
In other Cardinal Health news, insider Ola M. Snow sold 28,151 shares of the business's stock in a transaction that occurred on Tuesday, August 19th. The stock was sold at an average price of $148.94, for a total value of $4,192,809.94. Following the completion of the sale, the insider owned 15,431 shares in the company, valued at approximately $2,298,293.14. The trade was a 64.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Michelle D. Greene sold 13,500 shares of the business's stock in a transaction that occurred on Tuesday, August 19th. The shares were sold at an average price of $148.82, for a total value of $2,009,070.00. Following the completion of the sale, the insider owned 14,976 shares of the company's stock, valued at approximately $2,228,728.32. This represents a 47.41% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 271,676 shares of company stock valued at $40,489,525 in the last 90 days. Company insiders own 0.12% of the company's stock.
Wall Street Analysts Forecast Growth
CAH has been the subject of a number of analyst reports. Wells Fargo & Company reissued an "overweight" rating and set a $185.00 price objective (up from $183.00) on shares of Cardinal Health in a research report on Wednesday, August 13th. Argus set a $189.00 price objective on Cardinal Health in a research report on Friday, August 22nd. Citigroup reissued a "neutral" rating and set a $170.00 price objective (up from $157.00) on shares of Cardinal Health in a research report on Friday, June 13th. Robert W. Baird boosted their price objective on Cardinal Health from $197.00 to $203.00 and gave the stock an "outperform" rating in a research report on Wednesday, August 13th. Finally, UBS Group reissued a "buy" rating on shares of Cardinal Health in a research report on Tuesday, August 12th. Eleven analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $165.93.
Check Out Our Latest Report on Cardinal Health
About Cardinal Health
(
Free Report)
Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home.
Further Reading
Want to see what other hedge funds are holding CAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cardinal Health, Inc. (NYSE:CAH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cardinal Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardinal Health wasn't on the list.
While Cardinal Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report